NCT04520074View on ClinicalTrials.gov

Adjuvant Chemotherapy of Three-step Regimen in BRCA1/2 Wide Type Ovarian Cancer (ACTS-2)

PHASE3RecruitingINTERVENTIONAL
Enrollment

590

Participants

Timeline

Start Date

October 8, 2021

Primary Completion Date

September 30, 2027

Study Completion Date

September 30, 2030

Conditions
Ovarian Cancer
Interventions
DRUG

Etoposide, Cyclophosphamide, Carboplatin/Cisplatin

CTX 400mg（250mg/m2）+VP-16 100mg (70mg/m2)d1-d3 iv 4w/6cycles , CBP(AUC=5) d1/CDDP 30mg/m2 d1-d2+CTX 600mg(400mg/m2)d1-d2 iv 8w/6cycles

Trial Locations (1)

200023

RECRUITING

Wu Xiaohua, Shanghai

All Listed Sponsors
lead

Fudan University

OTHER